The metabolic disease treatment landscape is transforming rapidly. While GLP-1 receptor agonists have demonstrated remarkable efficacy, addressing the full scope of metabolic dysfunction requires therapeutic diversity from the perspectives of mechanism, durability, and patient fit. This session examines complementary modalities, each offering distinct advantages. Small molecules - including neuroinflammation inhibitors, exercise mimetics, and metabolic modulators - provide mechanistic diversity with oral convenience. Genetic medicines enable durable upstream pathway modification with infrequent or one-time dosing. Protein therapeutics target growth factor pathways to optimize body composition and preserve lean mass. The discussion will address how mechanistically distinct approaches can work synergistically with incretin therapy - and with each other - to achieve outcomes beyond what any single modality delivers alone.